Literature DB >> 9869164

Inhibition of lupus anticoagulant activity by hexagonal phase phosphatidylethanolamine in the presence of prothrombin.

J Rauch1, M Tannenbaum, C Neville, P R Fortin.   

Abstract

We have previously demonstrated that lupus anticoagulant antibodies from patients with systemic lupus erythematosus (SLE) specifically recognize hexagonal (II) phase phosphatidylethanolamine (PE), but not bilayer PE (Thromb Haemost 1989; 62: 892). In those studies, the involvement of proteins in this recognition was not evaluated. To address this issue, we have isolated IgG lupus anticoagulant antibodies from the plasma of SLE patients and evaluated the inhibition of lupus anticoagulant activity by hexagonal (II) phase PE in the presence and absence of purified plasma proteins. All six of the IgG lupus anticoagulant antibodies tested were inhibited by hexagonal (II) phase PE in the presence, but not the absence, of human prothrombin. In contrast, little or no inhibition was observed with prothrombin alone or with PE in combination with either beta2-glycoprotein I or annexin V. These data indicate that, for certain lupus anticoagulant antibodies, inhibition by hexagonal (II) phase PE is dependent on prothrombin, suggesting that these antibodies recognize a complex of PE and prothrombin.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9869164

Source DB:  PubMed          Journal:  Thromb Haemost        ISSN: 0340-6245            Impact factor:   5.249


  10 in total

Review 1.  Is testing for antiphosphatidylethanolamine antibodies clinically useful?

Authors:  Marielle Sanmarco
Journal:  Curr Rheumatol Rep       Date:  2011-02       Impact factor: 4.592

Review 2.  Clinical Risk Assessment in the Antiphospholipid Syndrome: Current Landscape and Emerging Biomarkers.

Authors:  Shruti Chaturvedi; Keith R McCrae
Journal:  Curr Rheumatol Rep       Date:  2017-07       Impact factor: 4.592

Review 3.  Anti-phospholipid antibodies (aPL) and apoptosis: prothrombin-dependent aPL as a paradigm for phospholipid-dependent interactions with apoptotic cells.

Authors:  Joyce Rauch; Paolo D'Agnillo; Rebecca Subang; Jerrold S Levine
Journal:  Thromb Res       Date:  2004       Impact factor: 3.944

4.  Antiphospholipid antibodies and thrombosis: association with acquired activated protein C resistance in venous thrombosis and with hyperhomocysteinemia in arterial thrombosis.

Authors:  Jeannine Kassis; Carolyn Neville; Joyce Rauch; Lambert Busque; Erika R Chang; Lawrence Joseph; Martine Le Comte; Rebecca Subang; Paul R Fortin
Journal:  Thromb Haemost       Date:  2004-12       Impact factor: 5.249

5.  Association of autoantibodies to heat-shock protein 60 with arterial vascular events in patients with antiphospholipid antibodies.

Authors:  Mélanie Dieudé; José A Correa; Carolyn Neville; Christian Pineau; Jerrold S Levine; Rebecca Subang; Carolina Landolt-Marticorena; Jiandong Su; Jeannine Kassis; Susan Solymoss; Paul R Fortin; Joyce Rauch
Journal:  Arthritis Rheum       Date:  2011-08

6.  Antibodies against oxidized phospholipids in laboratory tests exploring lupus anti-coagulant activity.

Authors:  R Rolla; M Vidali; R Serino; P Pergolini; E Albano; G Bellomo
Journal:  Clin Exp Immunol       Date:  2007-05-04       Impact factor: 4.330

7.  The presence of multiple prothrombotic risk factors is associated with a higher risk of thrombosis in individuals with anticardiolipin antibodies.

Authors:  Marie Hudson; Andrée-Laure Herr; Joyce Rauch; Carolyn Neville; Erika Chang; Reda Ibrahim; Chantal Séguin; Jeannine Kassis; Lambert Busque; Paul R Fortin
Journal:  J Rheumatol       Date:  2003-11       Impact factor: 4.666

8.  Thromboembolic risk in patients with high titre anticardiolipin and multiple antiphospholipid antibodies.

Authors:  Carolyn Neville; Joyce Rauch; Jeannine Kassis; Erika R Chang; Lawrence Joseph; Martine Le Comte; Paul R Fortin
Journal:  Thromb Haemost       Date:  2003-07       Impact factor: 5.249

9.  Antiphospholipid antibodies predict imminent vascular events independently from other risk factors in a prospective cohort.

Authors:  Carolyn Neville; Joyce Rauch; Jeannine Kassis; Susan Solymoss; Lawrence Joseph; Patrick Belisle; Jerrold S Levine; Paul R Fortin
Journal:  Thromb Haemost       Date:  2009-01       Impact factor: 5.249

10.  The persistence of anticardiolipin antibodies is associated with an increased risk of the presence of lupus anticoagulant and anti-beta2-glycoprotein I antibodies.

Authors:  C Neville; J Rauch; J Kassis; S Solymoss; L Joseph; P Belisle; R Subang; E R Chang; P R Fortin
Journal:  Rheumatology (Oxford)       Date:  2006-03-01       Impact factor: 7.580

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.